Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier 
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • Biomarkers and Companion diagnostics: Payer Insights
    Learn More Biomarkers and Companion diagnostics: Payer Insights
    What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...
  • AI in Medical Diagnostics
    Learn More AI in Medical Diagnostics
    Evaluating the potential of artificial intelligence to revolutionise and expand medical diagnostics Artificial intelligence (AI) driven technologies have already radically changed practice and outcomes in medical...
  • Health Insurance Disruptors: Going Digital
    Learn More Health Insurance Disruptors: Going Digital
    Health insurance: how to thrive in an increasingly digital health world Health insurers are being challenged to develop a portfolio of digital services with limited knowledge of their effectiveness and at a considerable...
  • Innovative drugs: Mapping the Pricing and Reimbursement Landscape (2020)
    Learn More Innovative drugs: Mapping the Pricing and Reimbursement Landscape (2020)
    Drug innovation is delivering highly-effective medicines that significantly improve patient outcomes and, in some cases, are curative of disease. Yet of the 55 medicines that were approved in the US between January 2018...
  • Interoperability in Health
    Learn More Interoperability in Health
    Experts agree interoperability will unlock considerable value across healthcare Interoperability—enabling information systems to share data—offers a wealth of opportunities for multiple health stakeholders,...
  • Pricing Transparency in Pharma
    Learn More Pricing Transparency in Pharma
    Pharma challenged to engage and shape the drug pricing transparency debate Anxieties about rising drug prices is fuelling an ever louder global demand for price transparency—and reformers are getting their message...
  • Regulating Digital Health
    Learn More Regulating Digital Health
    As digital health progressively enters mainstream therapy, how should it be regulated and to what outcome? Digital health is booming and as investment in digital health technology grows more products and services will...
  • The Future of Disease Interception
    Learn More The Future of Disease Interception
    What does pharma need to do to develop this radical health model of the future? Disease interception is a novel healthcare model that identifies, treats and sometimes cures disease before it is fully manifested. There...
  • The Future of Personalised Medicine: The Role of Simulation and Digital Twins
    Learn More The Future of Personalised Medicine: The Role of Simulation and Digital Twins
    Beyond the hype, where might simulation and digital twin technology deliver value for pharma? There is considerable excitement about the potential for simulation and digital twin technology to drive the personalised...
  • The Future of Virtual Healthcare
    Learn More The Future of Virtual Healthcare
    What strategy should pharma be pursuing in virtual healthcare? Applications for virtual healthcare engagement are quickly evolving beyond websites and apps towards advanced tools such as virtual assistants and virtual...
  • The Impact of 5G on Healthcare
    Learn More The Impact of 5G on Healthcare
    Health insurance: how to thrive in an increasingly digital health world 5G wireless network technology has the potential to revolutionise pharma's business. Combined with advances in artificial intelligence and machine...
  • The Future of Key Account Management in Pharma
    Learn More The Future of Key Account Management in Pharma
    Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
  • Trends in Investment by Big Pharma
    Learn More Trends in Investment by Big Pharma
    What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...
  • Benchmarking Key Account Management Capabilities (2019)
    Learn More Benchmarking Key Account Management Capabilities (2019)
    What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
  • Biosimilars: The Importance of Real-World Evidence (2019)
    Learn More Biosimilars: The Importance of Real-World Evidence (2019)
    Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...
  • Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Learn More Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved